Xgeva (denosumab for cancer SREs) — J0897 + Q5136, Q5157, Q5158 biosimilars

About Xgeva & the denosumab molecule FDA labels verified May 2026

Denosumab is a fully human IgG2 monoclonal antibody against RANK ligand (RANKL). By binding RANKL, denosumab prevents activation of osteoclasts — the cells responsible for tumor-driven bone resorption that produces skeletal-related events.

Xgeva (Amgen) is the FDA-approved denosumab product for cancer-related skeletal indications, dosed at 120 mg subcutaneously every 4 weeks. FDA-approved indications include prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors (initial approval Nov 2010), multiple myeloma SREs (added 2014), giant-cell tumor of bone in patients for whom surgical resection would result in severe morbidity (2013), and hypercalcemia of malignancy refractory to bisphosphonate therapy (2014).

The same molecule is sold by Amgen as Prolia for osteoporosis at 60 mg subcutaneously every 6 months. Although both products bill under the same HCPCS J0897 ("Injection, denosumab, 1 mg"), they are not clinically interchangeable: the FDA-approved indications, doses, dosing intervals, packaging (Xgeva: 120 mg SDV; Prolia: 60 mg prefilled syringe), and biosimilar brand pairings differ. The dedicated Prolia reference lives at /drugs/prolia.

Sandoz's denosumab biosimilar (denosumab-bbdz) is marketed as Wyost for the Xgeva (cancer) indication and as Jubbonti for the Prolia (osteoporosis) indication — identical molecule, separately FDA-approved as different brands per indication. Both share HCPCS Q5136. Subsequent denosumab biosimilars (Q5157, Q5158) are both-indication products and substitute for Xgeva in cancer SRE indications.

Xgeva vs. Prolia — same molecule, two products FDA labels verified May 2026

This is the highest-stakes disambiguation on the denosumab page. Mis-billing across the line is a frequent audit finding because both products share HCPCS J0897.

Four-product denosumab biosimilar family (Xgeva line) CMS HCPCS + FDA verified May 2026

Reference plus three biosimilars. All denosumab biosimilars approved through 2026 are both-indication products (Prolia line + Xgeva line) and ship as separately packaged 120 mg/1.7 mL single-dose vials for the cancer indication. All four codes use 1 unit = 1 mg.

All four products share the same molecular structure and the same Warnings & Precautions (severe hypocalcemia, MRONJ, AFF, embryo-fetal toxicity). Pre-treatment workup and monitoring requirements are identical across the family at the Xgeva dose schedule.

Dosing, loading regimens, and pre-treatment workup FDA Xgeva label + NCCN supportive care v1.2026

120 mg subcutaneously every 4 weeks for SREs and MM. Loading doses required for GCTB (weekly × 3 in cycle 1) and HCM (weekly × 3 + day 29). The pre-treatment workup is the dominant clinical-policy hurdle.

Dosing matrix by indication

Standard administration

• Dose: 120 mg SC (full vial of 120 mg / 1.7 mL)
• Site: upper arm, upper thigh, or abdomen
• Form: single-dose vial (no reconstitution; draw entire vial; no IV push)
• Co-therapy (FDA label): calcium ≥ 500 mg/day + vitamin D ≥ 400 IU/day during therapy (oncology populations and CKD patients commonly need higher calcium — 1,000 mg/day is typical)

Pre-treatment workup checklist

Document each item before submitting the prior authorization. Most Xgeva denials trace to one of these missing pieces.

• Cancer diagnosis with bone involvement — pathology + imaging documentation of bone metastases, multiple myeloma with osseous disease, GCTB diagnosis, or hypercalcemia of malignancy refractory to bisphosphonates
• Serum calcium + 25-OH vitamin D — correct deficiency before initiation; calcium ALBUMIN-corrected (cancer patients commonly have hypoalbuminemia that masks hypocalcemia)
• Renal function (CrCl) — CrCl < 30 mL/min and dialysis patients are at substantially higher hypocalcemia risk; check calcium more frequently
• Baseline dental assessment with documented clearance — complete invasive dental work (extractions, implants, periodontal surgery) BEFORE initiation when feasible (MRONJ risk)
• Pregnancy testing in women of child-bearing potential (embryo-fetal toxicity; effective contraception required during therapy and for 5 months after)
• Prior bisphosphonate exposure — document zoledronic acid / pamidronate trial, response, intolerance, or contraindication where step therapy is required

Indications & eligibility

• Prevention of skeletal-related events in patients with bone metastases from solid tumors (initial FDA approval November 2010)
• Prevention of skeletal-related events in patients with multiple myeloma (FDA expansion January 2018)
• Giant-cell tumor of bone (GCTB) in adults and skeletally mature adolescents where the tumor is unresectable or where surgical resection would result in severe morbidity (FDA approval June 2013)
• Hypercalcemia of malignancy refractory to bisphosphonate therapy (FDA approval December 2014)

NDC reference — all four products FDA NDC Directory verified May 2026

All four Xgeva-line products ship as 120 mg / 1.7 mL single-dose vials. Pad to 11 digits with leading zero in the labeler segment for CMS-1500 Box 24A. NDCs reflect manufacturer billing references; verify against the actual carton at billing time, especially for newer biosimilars.

Xgeva (J0897) — Amgen labeler 55513

Wyost (Q5136) — Sandoz

denosumab-bmwo (Q5157) — Celltrion (Xgeva line)

denosumab-bnht (Q5158)

Administration codes CPT verified May 2026

Xgeva is a non-chemotherapeutic subcutaneous injection. Use 96372 — do NOT use 96401 (chemo SC) and do NOT use 96365 / 96413 (IV codes). Some payers historically accepted 96401 for the oncology setting; CPT correct coding remains 96372.

Why 96372 — non-chemo SC therapeutic injection

Xgeva is administered as a single subcutaneous injection drawn from a single-dose vial. The injection meets the CPT 96372 definition: "therapeutic, prophylactic, or diagnostic injection (specify substance); subcutaneous or intramuscular." There is no infusion time, no observation period beyond standard practice, and no chemotherapy classification — denosumab is an anti-resorptive monoclonal antibody given for prevention of skeletal-related events.

Bundle considerations: 96372 is typically billed once per encounter regardless of cancer indication. Same-day chemotherapy infusion (e.g., a 96413 hour of cytotoxic IV) is reported separately with its own CPT and modifier 59 (or appropriate X-modifier) on the 96372 if NCCI edits apply at the payer.

Modifiers — JZ standard, JW rare, biosimilar suffix awareness CMS verified May 2026

Single-dose vial at matched dose almost never triggers waste at the standard 120 mg regimen. JZ is the dominant modifier; JW is rare. Biosimilar nonproprietary suffixes (-bbdz, -bmwo, -bnht) drive the HCPCS-to-NDC pairing.

JZ — required when no drug discarded

Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. For Xgeva, JZ applies on every standard 120 mg dose — the full 120 mg / 1.7 mL vial is administered with no waste. Append JZ to the J0897 / Q5136 / Q5157 / Q5158 line.

JW — only if drug discarded

JW is rare for Xgeva because the dose is matched to the vial. JW would apply only if a vial was broken, contaminated, or unable to be administered — in which case bill the discarded units on a separate line with JW and document the circumstance. CMS requires the wastage be documented in the medical record. Worked example: vial broken during draw, 60 mg discarded → Line 1: J0897 60 units (administered), Line 2: J0897 60 units JW (discarded); both with N4 NDC qualifier.

Biosimilar nonproprietary suffixes

• denosumab-bbdz — Sandoz; Wyost (Xgeva indication) / Jubbonti (Prolia indication); HCPCS Q5136
• denosumab-bmwo — Celltrion; HCPCS Q5157
• denosumab-bnht — verify trade name; HCPCS Q5158

The four-letter suffix is FDA-mandated under the BsUFA biosimilar naming convention and appears in the FDA "Purple Book" entry, on the carton, and in CMS HCPCS descriptors. Match the suffix to the Q-code: -bbdz ↔ Q5136, -bmwo ↔ Q5157, -bnht ↔ Q5158. Submitting the reference J0897 when a biosimilar was administered triggers a denial.

Modifier 25 — same-day E/M

Append modifier 25 to the same-day E/M code if a significant, separately identifiable evaluation occurred (response-assessment encounter, treatment-decision review, lab review for hypocalcemia). Routine pre-injection check-in is bundled into the 96372 administration code.

ICD-10-CM diagnosis matrix — cancer indications FY2026 verified May 2026

Use the most specific code supported by chart documentation. Each Xgeva indication has a distinct ICD-10 family. Pair primary cancer C-code with secondary bone-metastasis, MM, GCTB, or HCM codes as appropriate.

Site of care & place of service Verified May 2026

Xgeva administration is dominated by oncology offices and infusion centers because the patient is typically already in active cancer care. HOPD is common when the patient is in concurrent IV chemotherapy. Home administration is rare for Xgeva (vs. occasional Prolia home dosing) due to the q4w cadence and oncology population.

Claim form field mapping Amgen + payer billing PDFs

CMS-1500 / 837P (physician office, POS 11) example for a 120 mg Xgeva dose with concurrent oncology-suite supportive care.

Worked example — standard 120 mg Xgeva for prostate cancer bone mets (POS 11)

Source: Amgen Assist 360 Xgeva Reimbursement Guide; Sandoz One Source Wyost billing reference; NCCN supportive care guidelines v1.2026.

Payer policies — Xgeva for cancer SREs Reviewed May 2026

Medicare Part B covers Xgeva for FDA-approved cancer indications under MAC articles (no single national LCD; jurisdiction-dependent). Commercial payers add biosimilar-preferred designations and, in some cases, step therapy through IV zoledronic acid.

CMS coverage — oncology MAC articles

There is no single national LCD for Xgeva — coverage flows from MAC-specific oncology articles and the broader Part B reasonable-and-necessary standard for FDA-approved indications. Most MACs cover J0897 (and the biosimilar Q-codes) when:

• FDA-approved cancer indication is documented (bone mets from solid tumor, MM with osseous disease, GCTB unresectable, HCM refractory to bisphosphonates)
• Pre-treatment calcium and vitamin D status confirmed (or correction underway)
• For HCM: prior bisphosphonate therapy with documented refractoriness
• For GCTB: documentation that surgical resection is impossible or would result in severe morbidity
• Patient signs informed consent regarding MRONJ + AFF risks (where required by institution)

Reference: CMS Medicare Coverage Database — search jurisdiction-specific MAC articles for denosumab oncology indications.

Commercial payer snapshot — 2026

What to document for approval

• FDA-approved indication (bone mets / MM / GCTB / HCM) with diagnostic confirmation
• For bone mets: imaging (CT / MRI / bone scan) documenting osseous involvement
• For MM: marrow biopsy + osseous lesion documentation
• For GCTB: surgical-impossibility / severe-morbidity rationale
• For HCM: prior bisphosphonate trial (zoledronic acid or pamidronate) with documented refractoriness
• Pre-treatment workup: calcium, 25-OH vitamin D, CrCl, baseline dental assessment
• Where step therapy applies: zoledronic acid trial / contraindication (CrCl < 30 mL/min, infusion reaction, acute-phase response intolerance)

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. All four denosumab codes (J0897 + Q5136 / Q5157 / Q5158) refresh together each quarter; the Xgeva 120 mg dose calculations use the same per-mg ASP as the Prolia 60 mg dose.

Cross-product price comparison (Q2 2026 ASP+6%, 120 mg Xgeva dose)

Annualized exposure (~13 doses/year)

• J0897 reference: ~$46,030/year drug spend (pre-sequestration)
• Q5136 Wyost: ~$43,546/year
• Q5157 (lowest): ~$40,886/year
• Q5158: ~$46,483/year

ASP refreshes quarterly. CMS publishes the Q3 2026 file on or about July 1, 2026, with rates effective July 1 – September 30. The live snapshot above binds to whichever CMS quarter is currently loaded.

Coverage

Medicare Part B covers denosumab for FDA-approved cancer indications (J0897 and biosimilars) under MAC-specific oncology articles. This is a buy-and-bill medical-benefit drug — NOT Part D. Most MACs cover all four denosumab codes for the Xgeva-line indications when paired with appropriate ICD-10 documentation.

Canonical code source: CMS HCPCS quarterly update file.

Patient assistance — Amgen Assist 360 + Safety Net + foundations Manufacturer sites verified May 2026

• Xgeva (Amgen): Amgen Assist 360 reimbursement support (benefits investigation, prior authorization assistance, claims appeals); Xgeva Co-pay Program for eligible commercially-insured patients with no income cap on the standard program; Amgen Safety Net Foundation (504(c)(3) independent foundation) for free drug to qualifying uninsured patients meeting income eligibility. Phone: 1-888-4ASSIST (1-888-427-7478). Independent foundations (PAN Foundation, HealthWell Foundation, Patient Advocate Foundation) for Medicare patients — verify open funds quarterly (bone-metastasis SRE prevention fund availability fluctuates).
• Wyost (Sandoz): Sandoz One Source. Phone: 1-844-726-3691. Co-pay support and PAP for free drug.
• Q5157 (Celltrion): Celltrion Connect. Phone: 1-866-466-4046. Co-pay support and PAP for free drug.
• Q5158 (denosumab-bnht): verify manufacturer assistance program at billing time.

Common denials & how to fix them

Frequently asked questions

Xgeva vs. Prolia — are they the same drug with a different J-code?

Same molecule (denosumab, Amgen), same HCPCS J0897, but two separately FDA-approved products with different indications, doses, and schedules. Xgeva is 120 mg subcutaneous every 4 weeks for cancer-related skeletal events (bone metastases from solid tumors, multiple myeloma, giant-cell tumor of bone, hypercalcemia of malignancy). Prolia is 60 mg subcutaneous every 6 months for osteoporosis. Both bill J0897 (1 unit = 1 mg), but Xgeva is 120 units per dose and Prolia is 60 units. Submitting 60 units with a cancer bone-mets diagnosis under-bills Xgeva by half; submitting 120 units with an osteoporosis diagnosis triggers a clinical-policy mismatch. See the /drugs/prolia reference for the osteoporosis line.

Which denosumab biosimilars are interchangeable both ways (Prolia and Xgeva)?

All denosumab biosimilars FDA-approved through 2025–2026 carry approvals for BOTH the Prolia (osteoporosis) and Xgeva (cancer SRE) indications — including denosumab-bbdz (Sandoz; Jubbonti for Prolia line, Wyost for Xgeva line; HCPCS Q5136), denosumab-bmwo (Celltrion; Q5157), and denosumab-bnht (Q5158). The reference molecule is the same; the products ship as separately packaged SKUs per indication (60 mg/1 mL PFS for Prolia line, 120 mg/1.7 mL SDV for Xgeva line). Match HCPCS to the actual carton drawn and pair with the appropriate cancer or osteoporosis ICD-10.

What is the loading-dose regimen for Xgeva in giant-cell tumor of bone?

For GCTB, Xgeva is given as 120 mg SC every 4 weeks with additional loading doses of 120 mg on days 8 and 15 of the first month of therapy (i.e., weekly × 3 in cycle 1, then q4w thereafter). For bone-metastasis SRE indications and multiple myeloma, NO loading is used — regimen is 120 mg SC q4w from cycle 1. For HCM refractory to bisphosphonates, dosing is days 1, 8, 15, 29, and q4w thereafter. The GCTB loading doses each bill as separate 120-unit J0897 claims; expect payer auto-edits that may need appeal documentation referencing the FDA label.

What baseline dental assessment is required before starting Xgeva?

MRONJ is the most consequential long-term safety issue with Xgeva — cumulative annual exposure is ~1,560 mg/year vs. ~120 mg/year for Prolia. Best practice (FDA label, AAOMS 2022 position paper, ASCO 2021 guidance): complete a baseline dental examination plus any planned invasive dental work (extractions, implants, periodontal surgery) BEFORE the first Xgeva dose; document the clearance in the chart; maintain rigorous oral hygiene during therapy; defer non-emergent invasive dental procedures during active therapy when feasible. Patients with poor dentition, active periodontal disease, or planned major dental work should defer Xgeva initiation until dental clearance is obtained.

How is hypocalcemia managed in patients on Xgeva?

Severe hypocalcemia is the #1 acute safety issue. The FDA label requires correction of pre-existing hypocalcemia BEFORE initiation; calcium ≥ 500 mg/day plus vitamin D ≥ 400 IU/day during therapy (oncology populations often need 1,000 mg calcium); and serum calcium monitoring at baseline and within 14 days of EACH dose in high-risk patients (advanced CKD with CrCl < 30 mL/min, dialysis, vitamin D deficiency, prior bisphosphonate exposure, hypoparathyroidism). Hypocalcemia (E83.51) is an absolute contraindication until corrected. Monitoring is more aggressive than the Prolia regimen because Xgeva cumulative exposure is ~13× higher.

Is prior bisphosphonate therapy required before Xgeva approval?

Most Medicare MACs and commercial payers do NOT require step therapy through IV bisphosphonates (zoledronic acid / pamidronate) before Xgeva in the bone-metastasis SRE indication — Xgeva and zoledronic acid are considered first-line alternatives per NCCN supportive care guidelines. However, some commercial plans (UnitedHealthcare, certain BCBS plans) have moved zoledronic acid (J3489) and biosimilars (Q5101) ahead of Xgeva on preferred-product lists due to substantially lower cost. Document the rationale (renal impairment with CrCl < 30 mL/min that contraindicates zoledronic acid, infusion-reaction history, acute-phase-response intolerance). For GCTB and HCM refractory to bisphosphonates, Xgeva is the preferred agent with no step-therapy hurdle.

What guidance applies for biosimilar conversion in the Xgeva line?

UnitedHealthcare, Aetna, and several BCBS plans are mandating denosumab biosimilars (Q5136 Wyost / Q5157 / Q5158) over reference Xgeva J0897 in 2026 commercial medical policies. The biosimilars approved through 2026 are both-indication products — they substitute for Xgeva in cancer SRE indications. Operationally: verify the payer’s preferred-product list at billing time, draw the appropriate-brand 120 mg / 1.7 mL vial, match HCPCS to NDC, and pair with the cancer ICD-10. Billing reference J0897 when a biosimilar was administered (or vice versa) is a denial trigger and an audit finding.

What is the Q2 2026 Medicare reimbursement for Xgeva?

Q2 2026 ASP+6% for J0897 is approximately $29.507 per 1 mg unit. A standard 120 mg Xgeva dose = 120 units × $29.507 ≈ $3,540.84 before sequestration (~$3,470 after ~2% sequester). Biosimilars are priced lower: Q5157 ~$26.209/unit ($3,145.08 per 120 mg dose), Q5136 Wyost ~$27.914/unit ($3,349.68), Q5158 ~$29.797/unit ($3,575.64). Annualized at ~13 doses/year, drug spend runs roughly $41K–$46K/year pre-sequestration. ASP refreshes quarterly — see the live snapshot above.

What FDA warnings apply to Xgeva?

Denosumab for cancer SREs does not carry a formal FDA Boxed Warning, but the prescribing information includes multiple high-severity Warnings & Precautions: severe hypocalcemia (correct before initiation; high risk in advanced CKD / dialysis); medication-related osteonecrosis of the jaw (MRONJ) — complete invasive dental work before initiation when feasible (higher risk than Prolia due to cumulative dose); atypical femoral fractures (AFF) — bilateral hip/thigh pain warrants imaging; severe musculoskeletal pain; embryo-fetal toxicity — effective contraception required during therapy and for 5 months after the last dose; multiple vertebral fractures (MVF) after discontinuation — less prominent in the Xgeva regimen than in Prolia but documented; transition planning recommended for patients stopping long-term denosumab.

Source documents

1. FDA Xgeva label (BLA 125320, Amgen)
   Reference denosumab prescribing information for cancer SREs, GCTB, HCM; W&P; loading-dose regimens
2. AAPC — HCPCS J0897 (denosumab)
   Code descriptor and crosswalk reference (covers both Xgeva and Prolia)
3. AAPC — HCPCS Q5136 (Wyost / Jubbonti — denosumab-bbdz)
   First FDA-approved denosumab biosimilar code descriptor (Sandoz; both-indication approval)
4. AAPC — HCPCS Q5157 (denosumab-bmwo)
   Celltrion denosumab biosimilar code descriptor
5. AAPC — HCPCS Q5158 (denosumab-bnht)
   Newer denosumab biosimilar code descriptor — verify trade name and manufacturer
6. FDA Prolia label (current revision, BLA 125320)
   Companion osteoporosis label for Xgeva vs. Prolia disambiguation
7. FDA Wyost / Jubbonti label (BLA 761362, Sandoz)
   First FDA-approved denosumab biosimilar with interchangeability (March 2024)
8. NCCN Clinical Practice Guidelines — Supportive Care (Bone Health, v1.2026)
   First-line SRE prevention options including denosumab vs. zoledronic acid in solid tumors and multiple myeloma
9. NCCN Clinical Practice Guidelines — Multiple Myeloma (current version)
   SRE prevention guidance in MM (denosumab vs. IV bisphosphonate)
10. Xgeva HCP / Amgen Assist 360
    Manufacturer dosing, billing, and reimbursement guides; Co-pay Program and Safety Net Foundation
11. Sandoz One Source — Wyost
    Sandoz Xgeva-indication biosimilar billing reference; patient assistance program (1-844-726-3691)
12. Celltrion Connect — denosumab biosimilar (Q5157)
    Celltrion biosimilar billing reference; patient assistance program (1-866-466-4046)
13. AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaw (2022 update)
    Dental clearance and MRONJ prevention guidance for antiresorptive therapy
14. ASCO Guideline — Role of Bone-Modifying Agents in Metastatic Breast Cancer (2021)
    SRE-prevention agent selection (denosumab vs. zoledronic acid) and dental clearance
15. UnitedHealthcare — Denosumab Commercial Medical Drug policy
    2026 step-therapy and biosimilar-preferred designation criteria (covers both Xgeva and Prolia lines)
16. Aetna Clinical Policy Bulletin — Bone Metastases & Bone Modifying Agents
    Coverage criteria for denosumab in cancer SRE prevention
17. CMS — Medicare Part B Drug ASP Pricing File
    Q2 2026 quarterly file (J0897, Q5136, Q5157, Q5158)
18. CMS — HCPCS quarterly update file
    Canonical HCPCS code source for denosumab family
19. CMS — JW / JZ modifier guidance
    Single-dose-container waste reporting (effective 7/1/2023)

Refresh cadence

Reviewer

Change log

• May 22, 2026 — Initial publication of the Xgeva (denosumab for cancer SREs) reference; completes the Prolia/Xgeva denosumab pair. ASP data: Q2 2026 (J0897, Q5136, Q5157, Q5158). Disambiguation from Prolia (osteoporosis) line emphasized as #1 denial driver. GCTB and HCM loading regimens covered. MRONJ + hypocalcemia + AFF warnings included. Multi-indication ICD-10 matrix (bone mets / MM / GCTB / HCM).

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File for all four denosumab codes (shared with the Prolia line). Payer policies are read directly from each payer’s published medical policy documents. We do not paraphrase from billing-software vendor blogs. Where manufacturer guidance and payer policy diverge (e.g., site-of-care steering, biosimilar substitution timing), we surface the conflict rather than picking a side.

Found an error? Email hello@carecostestimate.com.